Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus
暂无分享,去创建一个
Mark Woodward | Bruce Neal | John Simes | Gerard Wong | Sophia Zoungas | Michel Marre | Bryan Williams | Bronwyn A Kingwell | Peter J Meikle | Anthony Rodgers | John Chalmers | M. Woodward | G. Hillis | B. Williams | P. Meikle | A. Tonkin | A. Rodgers | N. Poulter | M. Marre | P. Mundra | J. Chalmers | B. Neal | J. Simes | B. Kingwell | S. Zoungas | P. Nestel | M. McConville | N. Mellett | D. Sullivan | Gerard Wong | Christopher K. Barlow | E. Barnes | Graham S Hillis | Zahir H Alshehry | Piyushkumar A Mundra | Christopher K Barlow | Natalie A Mellett | Malcolm J McConville | Andrew M Tonkin | David R Sullivan | Elizabeth H Barnes | Paul J Nestel | Neil R Poulter | Z. Alshehry | Zahir H. Alshehry
[1] P. Pais,et al. Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease , 2016, Journal of the American Heart Association.
[2] Gretchen A. Stevens,et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants , 2016, Lancet.
[3] P. Meikle,et al. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice. , 2015, Atherosclerosis.
[4] P. Meikle,et al. An Efficient Single Phase Method for the Extraction of Plasma Lipids , 2015, Metabolites.
[5] Christopher Leckie,et al. LICRE: unsupervised feature correlation reduction for lipidomics , 2014, Bioinform..
[6] D. Kass,et al. Inhibition of Glycosphingolipid Synthesis Ameliorates Atherosclerosis and Arterial Stiffness in Apolipoprotein E−/− Mice and Rabbits Fed a High-Fat and -Cholesterol Diet , 2014, Circulation.
[7] Alexey L. Pomerantsev. Principal Component Analysis (PCA) , 2014, Encyclopedia of Autism Spectrum Disorders.
[8] T. Spector,et al. Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.
[9] Y. Fujiki,et al. Topogenesis and Homeostasis of Fatty Acyl-CoA Reductase 1* , 2013, The Journal of Biological Chemistry.
[10] J. Shaw,et al. Plasma lipid profiling in a large population-based cohort[S] , 2013, Journal of Lipid Research.
[11] Adam Kowalczyk,et al. Plasma Lipid Profiling Shows Similar Associations with Prediabetes and Type 2 Diabetes , 2013, PloS one.
[12] R. Deckelbaum,et al. Omega-3 fatty acids: mechanisms underlying ‘protective effects’ in atherosclerosis , 2013, Current opinion in lipidology.
[13] T. Kurata,et al. Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome. , 2011, Atherosclerosis.
[14] I. Haviv,et al. Plasma Lipidomic Analysis of Stable and Unstable Coronary Artery Disease , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[15] Christophe Ladroue,et al. Comparative Lipidomics Profiling of Human Atherosclerotic Plaques , 2011, Circulation. Cardiovascular genetics.
[16] S. Carr,et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. , 2011, The Journal of clinical investigation.
[17] Mark Woodward,et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[18] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[19] D. Kelley,et al. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. , 2010, The Journal of nutritional biochemistry.
[20] Roger Newson,et al. Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .
[21] J. Danesh,et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.
[22] Y. Fujiki,et al. Posttranslational Regulation of Fatty Acyl-CoA Reductase 1, Far1, Controls Ether Glycerophospholipid Synthesis*♦ , 2010, The Journal of Biological Chemistry.
[23] N. J. Wareham,et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review , 2009, Diabetologia.
[24] B. Fuchs,et al. Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. , 2009, Current medicinal chemistry.
[25] Stephen Colagiuri,et al. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study , 2009, The Medical journal of Australia.
[26] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[27] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[28] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[29] Anushka Patel,et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.
[30] A. Keech,et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. , 2003, Diabetes care.
[31] R. Stocker,et al. Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice. , 2002, Journal of lipid research.
[32] R. Holman,et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). , 2001, Clinical science.
[33] R. Collins,et al. Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation , 2001 .
[34] R. Murphy,et al. Inflammatory Platelet-activating Factor-like Phospholipids in Oxidized Low Density Lipoproteins Are Fragmented Alkyl Phosphatidylcholines* , 1999, The Journal of Biological Chemistry.
[35] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[36] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[37] A. Bhunia,et al. Oxidized low density lipoproteins stimulate galactosyltransferase activity, ras activation, p44 mitogen activated protein kinase and c-fos expression in aortic smooth muscle cells. , 1997, Glycobiology.
[38] W. Harris,et al. n-3 fatty acids and serum lipoproteins: animal studies. , 1997, The American journal of clinical nutrition.
[39] H. Wieland,et al. Gangliosides in normal human serum. Concentration, pattern and transport by lipoproteins. , 1989, European journal of biochemistry.
[40] A. J. Valente,et al. Atherosclerosis as an Inflammatory Process , 1985, Annals of the New York Academy of Sciences.
[41] H. Akaike. A new look at the statistical model identification , 1974 .
[42] B. Norrving,et al. Global atlas on cardiovascular disease prevention and control. , 2011 .
[43] Advance Management Committee. Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease – preterax and diamicron MR controlled evaluation , 2001, Diabetologia.
[44] W. Harris,et al. n-3 fatty acids and serum lipoproteins: human studies. , 1997, The American journal of clinical nutrition.
[45] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[46] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .